Onychomycosis: New therapies for an old disease

Western Journal of Medicine

Volumn 165, Issue 6, 1996, Pages 349-351

  Gupta, Aditya K ^a   Scher, Richard K ^b   De Doncker, Piet ^c   Sauder, Daniel N ^a   Shear, Neil H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; CICLOPIROX; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE; TIOCONAZOLE;

AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; MENSTRUATION DISORDER; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; RASH; VERTIGO;

AGED; ANTIFUNGAL AGENTS; FEMALE; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; MALE; NAPHTHALENES; ONYCHOMYCOSIS; TRICHOPHYTON;

EID: 0030447262     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Korting HC, Schäfer-Körung M: Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol 1992; 128:243-248
2. Shear NH, Gupta AK: Terbinafine for the treatment of pedal onychomycosis: A foot closer to the promised land of cured nails. Arch Dermatol 1995; 131:937-942
3. Svejgaard E: Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Derm Venereol (Stockh) 1985;65:143-149
4. Hay RJ, Clayton YM, Griffiths WAD, Dowd PM: A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis. Br J Dermatol 1985; 112:691-696
5. Davies RR, Everall JD, Hamilton E: Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; 3:464-468
6. Tailor SAN, Gupta AK, Walker SE, Shear NH: Peripheral edema due to nifedipine-itraconazole interaction: A case report. Arch Dermatol 1996; 132:350-352
7. Villars VV, Jones TC: Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126:61-69
8. Robertson MH, Hanifin JM, Parker F: Oral therapy with ketoconazole for dermatophyte infections unresponsive to griseofulvin. Rev Infect Dis 1980; 2:578-581
9. Galimberti R, Negroni R, Iglesia de Elias Costa MR, Casalá AM: The activity of ketoconazole in the treatment of onychomycosis. Rev Infect Dis 1980; 2:596-598
10. Janssen PAJ, Symoens JE: Hepatic reactions during ketoconazole treatment. Am J Med 1983; 74:80-85
11. Lake-Bakaar G, Scheuer PI, Sherlock S: Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J 1987; 294:419-422
12. Stricker BHC, Blok APR, Bronkhorst FB, Van Parys GE, Desmet VJ: Ketoconazole-associated hepatic injury - A clinicopathological study of 55 cases. J Hepatol 1986; 3:399-406
13. Knight TE, Shikuma CY, Knight J: Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 25:398-400
14. Jones HE: Ketoconazole. Arch Dermatol 1982; 118:217-219
15. Ketoconazole, Physicians' Desk Reference, 48th edition, Montvale, NJ, Medical Economics, 1994, pp 1095-1096
16. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview - Part II. J Am Acad Dermatol 1994; 30:911-933
17. Gupta AK, Shear NH, Sauder DN: New antifungal agents. Curr Opin Dermatol 1993;2:200-206
18. Van Der Schroeff JG, Cirkel PKS, Crijns MB, et al: A randomised treatment duration-finding study of terbinafme in onychomycosis. Br J Dermatol 1992; 126:36-39
19. Goudfield MJD, Andrew L, Evans EGV: Short term treatment of dermatophyte onychomycosis with terbinatine. BMJ 1992; 304: H 51-1154
20. Arenas R, Donínguez-Chanit J, Fernández LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34:138-143
21. Bräutigam M, Nolting S, Schopf RE, et al: Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ Br Med J 1995; 311:919-922
22. Faergemann J, Anderson C, Hersle K, et al: Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32:750-753
23. De Doncker P, Decroix I, Pierard OE, et al: Itraconazole pulse therapy is effective in the treatment of onychomycosis: A pharmacokinetic/pharmacodynamic and clinical evaluation. Arch Dermatol 1995;13:234-241
24. Willemsen W, De Doncker P, Willems J, et al: Post treatment itraconazole levels in nails, J Am Acad Dermatol 1992; 26:731-735
25. Roseeuw D, De Doncker P: New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29:S45-S50
26. Haneke E, Delescluse J, Plinck EPB, Haye RJ: The use of itraconazole in onychomycosis: A review. Eur J Dermatol 1994; 6:7-10
27. Baran R: Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol (Stockh) 1996;76:82-83
28. Nolting S, Brautigam M, Weidinger G: Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130(suppl 43):16-21
29. Roberts DT, Richardson MD, Dwyer PK, Donegan R: Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 3:39-42
30. Hay RJ, Clayton YM, Moore MK, Midgely: An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119:359-366
31. Itraconazole Product Monograph. Titusville, NJ, Janssen Pharmaceutica Inc. October 1995
32. Terbinafine Product Monograph. Hanover, NJ, Sandoz Pharmaceuticals Corporation, April 1996
33. Zaias N, Tosti A, Rebell G, et al: Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996; 34:302-304
34. Johnson M, Comaish JS, Shuster S: Nail is produced by the normal nail bed: A controversy resolved. Br J Dermatol 1991; 125:27-29
35. Johnson M, Shuster S: Continuous formation of nail along the bed. Br J Dermatol 1993; 128:277-280
36. Faergemann J, Zehender H, Denouël J, Millerioux L: Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol (Stockh) 1993; 73:305-309
37. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K: Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18:263-268
38. Finlay AY, Lever L, Thomas R, Dykes PJ: Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1:51-53
39. Munro CS, Rees JL, Shuster S: The unexpectedly rapid response of fungal nail infection to short duration therapy. Acta Derm Venereol (Stockh) 1992: 72:131-133
40. Finlay AY: Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126:28-32
41. Faergemann J, Zehender H, Millerioux L: Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19:121-126
42. Elewski BE: Onychomycosis. Fitzpatrick's J Clin Dermatol 1994; 1:48-54
43. Gupta AK, Sauder DN, Shear N: Antifungal agents (Reply to Letter). J Am Acad Dermatol 1995; 32:500-501
44. Itraconazole Product Monograph (International). Beerse, Belgium, Janssen Pharmaceutica Inc, 1996
45. Coldiron B: Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128:909-910
46. Kuokkanen K, Alava S: Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3:115-117
47. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview - Part I. J Am Acad Dermatol 1994; 30:677-698
48. Zaug M, Bergstraesser M: Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17:61-70
49. Haria M, Bryson HM: Amorolfine: A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995; 49:103-120
50. Gupta AK: Amorolfine: An overview. Drugs Today 1995; 31:145-153
51. Baran R: Amorolfine nail lacquer: A new transungual delivery system for nail mycoses. J Am Med Assoc SEA 1993; 9(suppl 4):5-6
52. Ulbricht H, Würz K: Therapy of onychomycosis due to moulds with ciclopirox nail lacquer. Mycoses 1994;37:97-100
53. Hay RJ, Mackie RM, Clayton YM: Tioconazole nail solution - An open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111-115